CC
Checkpoint Capital Portfolio holdings
AUM
$215M
This Quarter Return
+3.75%
1 Year Return
+27.24%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$150M
AUM Growth
+$150M
(+4.4%)
Cap. Flow
+$6.45M
Cap. Flow
% of AUM
4.31%
Top 10 Holdings %
Top 10 Hldgs %
92.23%
Holding
22
New
4
Increased
7
Reduced
6
Closed
4
Top Buys
| 1 |
Corcept Therapeutics
CORT
|
$6.9M |
| 2 |
AVDL
Avadel Pharmaceuticals
AVDL
|
$6.36M |
| 3 |
argenx
ARGX
|
$4.72M |
| 4 |
Rhythm Pharmaceuticals
RYTM
|
$4.14M |
| 5 |
Mirum Pharmaceuticals
MIRM
|
$3.23M |
Top Sells
| 1 |
SWTX
SpringWorks Therapeutics
SWTX
|
$12.4M |
| 2 |
Cytokinetics
CYTK
|
$2.8M |
| 3 |
Trevi Therapeutics
TRVI
|
$2.71M |
| 4 |
Ironwood Pharmaceuticals
IRWD
|
$2.28M |
| 5 |
Axsome Therapeutics
AXSM
|
$1.83M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Rhythm Pharmaceuticals
RYTM
$6.85B
| $35.8M | 23.91% |
825,500
+95,500
| +13% | +$4.14M |
|
|
2
argenx
ARGX
$43.6B
| $32.3M | 21.58% |
82,000
+12,000
| +17% | +$4.72M |
|
|
3
Cytokinetics
CYTK
$4.23B
| $13.3M | 8.9% |
190,000
-40,000
| -17% | -$2.8M |
|
|
AVDL
4
Avadel Pharmaceuticals
AVDL
$1.43B
| $11.8M | 7.92% |
701,387
+376,387
| +116% | +$6.36M |
|
|
5
Axsome Therapeutics
AXSM
$6.05B
| $10.6M | 7.06% |
132,437
-22,909
| -15% | -$1.83M |
|
|
6
Mirum Pharmaceuticals
MIRM
$3.71B
| $9.1M | 6.08% |
362,193
+128,534
| +55% | +$3.23M |
|
7
Protagonist Therapeutics
PTGX
$3.67B
| $8.11M | 5.42% |
280,301
+13,445
| +5% | +$389K |
|
|
8
Corcept Therapeutics
CORT
$7.35B
| $6.9M | 4.61% |
+273,776
| New | +$6.9M |
|
|
9
Ironwood Pharmaceuticals
IRWD
$214M
| $5.39M | 3.6% |
618,528
-261,472
| -30% | -$2.28M |
|
10
Phathom Pharmaceuticals
PHAT
$864M
| $4.73M | 3.16% |
445,161
+85,715
| +24% | +$910K |
|
|
ATYR
11
aTyr Pharma
ATYR
$527M
| $2.82M | 1.89% |
1,446,477
-57,077
| -4% | -$111K |
|
12
Verastem
VSTM
$569M
| $1.99M | 1.33% |
+168,739
| New | +$1.99M |
|
13
GH Research
GHRS
$837M
| $1.98M | 1.32% |
185,653
-108,292
| -37% | -$1.15M |
|
|
14
Trevi Therapeutics
TRVI
$883M
| $1.75M | 1.17% |
506,082
-786,234
| -61% | -$2.71M |
|
15
Applied Therapeutics
APLT
$71M
| $1.5M | 1% |
+220,000
| New | +$1.5M |
|
|
ALLK
16
DELISTED
Allakos
ALLK
| $968K | 0.65% |
767,964
+323,160
| +73% | +$407K |
|
17
Atara Biotherapeutics
ATRA
$84.6M
| $620K | 0.41% |
+892,853
| New | +$620K |
|
18
Aclaris Therapeutics
ACRS
$209M
| – | – |
-453,614
| Closed | -$476K |
|
19
Edgewise Therapeutics
EWTX
$1.51B
| – | – |
-33,000
| Closed | -$361K |
|
20
Disc Medicine
IRON
$2.07B
| – | – |
-10,000
| Closed | -$578K |
|
|
SWTX
21
DELISTED
SpringWorks Therapeutics
SWTX
| – | – |
-340,000
| Closed | -$12.4M |
|
22
SPDR S&P Biotech ETF
XBI
$5.07B
| – | – |
0
| – | – |
|